804,Sience Bldg,Haicang Hitech Zone,No 289 of Wenjiao Road Haicang,XiaMen,China/Fujian,China China
XIAMEN CIYUAN BIOTECH CO., LTD Magnetic drug nano-particles, Anti-cancer new drug, Multi-carrier, Multi-target range, Multi-target point, Postpone controlled release, Reversion of multi-drug resistance, Two cure ways by oral and nasal cavity. Our *0 new innovation drugs (such as Anti-Cancer, Anti-Aids, Anti-Dengue, Anti-Malaria, Anti-cerebral thrombus etc) were successful completion of the first time pilot plant test, now looking for investment and cooperation, technology transfer. The sample of this Anti-Cancer (Broad Spectrum), was sent to authoritative government department for testing, After inside coelom test of white rat, the test results were: *9.3% for cancer restraint rate of cervical cancer U*4, The result for toxicity test was: Maximum Tolerated Dose (TMD) is *5.2g/kg, equal **2 times of the clinical human dosage. The samples of pilot plant test were passed clinical preliminary test by more *0 patients, the preliminary verification of this clinical preliminary test: definite efficacy, higher security, and less side-effects.
Business Type
Manufacturing
Website
www.ciyuanbiotech.com
Year Established
2005
Number of Employees
6-10
Main Markets
Africa,Asia,Middle East
Products / Services
skin ointment, anti-cancer capsule, oil for youth pimple, oil for mosquito&insect bite, ichors absorbing powder
Factory Location
N/A
Factory Size
N/A
No. of Production Lines
0
Total Annual Purchase Volume
N/A
No. of R&D Staff
N/A
Quality Control
N/A
Certificates
N/A
Contract Manufacturing
N/A
Registered Capital
N/A
Ownership Type
N/A
Legal Representative / CEO
N/A
Export Percentage
N/A
Total Annual Sales Volume
N/A
No. of QC Staff
N/A
Contact Person
Mr. Yunching
Company
XIAMEN CIYUAN BIOTECH CO., LTD
Address
804,Sience Bldg,Haicang Hitech Zone,No 289 of Wenjiao Road Haicang, XiaMen, China/Fujian, China
Contact Person Mr. Yunching
Address 804,Sience Bldg,Haicang Hitech Zone,No 289 of Wenjiao Road Haicang, XiaMen, China/Fujian, China
